JPRN-jRCTs041190085已完成2 期
Targeted radiotherapy for malignant neuroendocrine tumors with I-131 metaiodobenzylguanidine (MIBG) (Targeted radiotherapy for malignant neuroendocrine tumors with I-131 metaiodobenzylguanidine (MIBG)) -phase2 trial
Seigo Kinuya0 个研究点目标入组 18 人开始时间: 2019年11月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
Eighteen patients with malignant neuroendocrine tumors were treated with 131I-MIBG. Health insurance has covered 131I-MIBG treatment during the study. The study was terminated in the middle because all scheduled participants requested to discontinue participation. In addition, no participant asked for 131I-MIBG treatment at a higher dose. We evaluated data obtained up to study discontinuation. Catecholamines and their metabolites were considered decreased or stable. No serious adverse effects were observed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients with histologically proven malignant neuroendocrine tumors
- •2) Patients with metastases, recurrent lesions or unresectable lesions
- •3) Positive I131-MIBg uptake
- •4) Performance Status (ECOG) 0or1, Patients with ADL adequate for treatment in an isolation room. Patients with limited ADL which can be compensated by the others under the approval of the ethical board.
- •5) Patients with written informed consent
- •(If a subject is minor who is 16 years of age or older) After informed consent for participating in the clinical study, a patient and a substitute have given their written consent.
- •(If the subject is under 16 years of age) After full informed consent to a substitute for participating in the clinical study and patient's informed assent, a substitute has given their written consent.
- •(Case in which it is difficult to obtain the consent of a subject alone who is not a minor under 16 years of age) After informed consent for participating in the clinical study, a substitute has given their written consent.
排除标准
- •1)Preg nant female and feeding female 2)Patients with disturbed consciousness
- •3)An expected life expectancy of less than 1 month4)Limited bone marrow capacity
- •Hb<9.0, WBC count<3,000, platelet count <100,000
- •5)Renal disorder
- •GFR<30 ml/min/1.73 m2
- •6)Risks for the central nerve compression syndrome that might be caused by lesion edema during the treatment
- •7) In case that medical practice and radiation management is difficult in an isolation room, In case of uncontrolled symptoms that require emergent medical cares, In case that urine manag ement is difficult, In case that understanding and cooperation cannot be obtained from family members
- •8) When medical staffs determine that treatment cannot be properly carried out.
研究者
相似试验
已完成
2 期
Targeted radiotherapy for malignant neuroendocrine tumors with MIBGMalignant neuroendocrine tumorsmalignant neuroendocrine tumors, I-131 MIBG therapyJPRN-jRCTs041180040Kinuya Seigo61
已完成
不适用
Targeted radiotherapy for malignant neuroendocrine tumors with I-131 metaiodobenzylguanidine (MIBG)malignant neuroendocrine tumorsJPRN-UMIN000002529Kanazawa University Hospital100
进行中（未招募）
不适用
Targeted radionuclide therapy of neuroendocrine tumours using 177Lu-DOTATATE combined with induced local tumour up-regulation of somatostatin receptor expression for increased tumour dosage and tumour to background ratio - NET Therapy 177Lu-DOTATATEEUCTR2012-000266-38-DKDepartment of Nuclear Medicine, Odense University Hospital50
招募中
2 期
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or ParagangliomaPheochromocytomaNeuroblastomaNCT00107289Memorial Sloan Kettering Cancer Center200
已完成
2 期
Targeted radiotherapy for chemotherapy resistant neuroblastoma with I-131 metaiodobenzylguanidine (MIBG)euroblastomaNeuroblastoma, I-131 MIBG therapyJPRN-jRCTs041180041Kinuya Seigo63